These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 12022338

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.
    J Clin Oncol; 2004 Dec 01; 22(23):4753-61. PubMed ID: 15570076
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS.
    J Urol; 2007 Jan 01; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [Abstract] [Full Text] [Related]

  • 9. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ.
    J Clin Oncol; 2005 Dec 01; 23(34):8671-8. PubMed ID: 16314627
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E, Arbeitsgemeinschaft Internistische Onkologie.
    J Clin Oncol; 2008 Mar 20; 26(9):1435-42. PubMed ID: 18349393
    [Abstract] [Full Text] [Related]

  • 15. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
    Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y.
    Hepatogastroenterology; 2003 Mar 20; 50(54):2259-63. PubMed ID: 14696512
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
    Sobrero A, Frassineti G, Falcone A, Dogliotti L, Rosso R, Di Costanzo F, Bruzzi P, INTACC.
    Br J Cancer; 2005 Jan 17; 92(1):24-9. PubMed ID: 15611795
    [Abstract] [Full Text] [Related]

  • 17. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
    Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jäger E.
    Cancer; 2007 May 01; 109(9):1897-904. PubMed ID: 17377918
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.
    Brulhart L, Ciurea A, Finckh A, Notter A, Waldburger JM, Kyburz D, Gabay C.
    Ann Rheum Dis; 2006 Sep 01; 65(9):1255-7. PubMed ID: 16540545
    [No Abstract] [Full Text] [Related]

  • 19. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Sep 01; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 20. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
    Kerkeni S, Marotte H, Miossec P.
    Muscle Nerve; 2008 Oct 01; 38(4):1343-5. PubMed ID: 18816604
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.